Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN.VN)

Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NervGen Pharma Begins Trading on Nasdaq Today GlobeNewswire - Thu Jan 8, 5:30AM CST

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 5.66 (-5.19%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS Newsfile - Wed Dec 17, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Announces Proposed Amendment to Warrants Newsfile - Fri Dec 12, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury Newsfile - Mon Nov 24, 2025

Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placeboParticipant-reported...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates Newsfile - Mon Nov 24, 2025

Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injuryCompleted a U.S. Food...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development Newsfile - Wed Nov 19, 2025

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development Newsfile - Tue Nov 18, 2025

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders Newsfile - Tue Aug 26, 2025

Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury Newsfile - Thu Aug 21, 2025

Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss modelsPromoted significant functional recovery and axonal regeneration in peripheral nerve injury modelsReinforced...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion Newsfile - Thu Jul 17, 2025

Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial ResultsVancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV:...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 7.850 (-2.85%)

Barchart Exclusives

Is Google Stock a Buy at New All-Time Highs in January 2026? Barchart - 12 minutes ago
Alphabet’s AI-driven rally looks justified by earnings strength, though the stock now prices in much of Wall Street’s optimism. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot